AbCellera Biologics EBIT

As of the most recent data (June 2026), ABCL shows a EBIT of $-200M. That compares with $-220M in the prior-year period — up 8.0% year over year. That is below the sector sector average of $-63M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ABCL's EBIT is now $-200M (was $-220M) — a 8.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether AbCellera Biologics is outperforming or lagging.

The its sector sector average EBIT is about $-63M. AbCellera Biologics is at $-200M, which is lower that average. That is roughly 227.2% below the sector mean. Use the comparison chart on this page to see how ABCL stacks up against individual peers as well.

Tracking ABCL's ebit over time shows whether AbCellera Biologics is scaling, shrinking, or reshaping that part of the business. The current reading is $-200M That compares with $-220M in the prior-year period — up 8.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has AbCellera Biologics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-200M) with ownership activity and broader fundamentals.